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Abstract: Results of several epidemiological studies have indicated that diabetes mellitus will become a global 
epidemic in the next decades, being more than 400 million the human subjects in the world affected by this dis-
ease in the 2030. Most of these subjects will be affected by type 2 diabetes mellitus (T2DM) whose diffusion is 
mainly related to excessive caloric upload, sedentary life and obesity. Typically, the treatment for T2DM is 
diet, weight control, physical activity or hypoglycaemic and/or lipid-lowering drugs. Unfortunately, these drugs often 
show low effectiveness or adverse side effects, thereby forcing patient to discontinue medical treatment. Nevertheless tra-
ditional medicine suggests the use of several formulations or medicinal foods to treat T2DM. Most of them are character-
ized by safety, low cost, effectiveness, and good availability. Before the advent of modern pharmacology, these remedies 
were used to treat diabetes and obesity or prevent their onset. Today, we know that their effectiveness is due to the pres-
ence of several bioactive compounds able to influence insulin signaling pathway and cellular metabolism. In the last dec-
ades, many efforts have been carried out to clarify their action mechanism. Here we provide a classification of the natural 
compounds that stimulate the insulin pathway, highlighting their effectiveness in controlling glycaemia on diabetic animal 
models or improving insulin signaling in cellular systems. 
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INTRODUCTION 
Insulin signaling is mediated by a complex and highly in-
tegrated network that controls many physiological processes 
[1]. Insulin receptor (IR), a tetrameric membrane protein 
consisting of two extracellular -subunits and two intracellu-
lar -subunits, is an allosteric enzyme in which the -
subunits inhibit the intrinsic tyrosine kinase activity of the -
subunits. Insulin binding to the -subunit enhances IR kinase 
activity thus triggering downstream signaling events such as 
insulin receptor substrates (IRSs) recruitment and phos-
phorylation. Tyr-phosphorylated IRS acts as a docking pro-
tein for intracellular adaptor proteins (e.g. the regulatory 
subunit of PI3K, and Grb2) which activate two main signal-
ing pathways: i) the PI3K-AKT/PKB pathway, which is re-
sponsible for most of the metabolic actions of insulin (stimu-
lation of glucose uptake; glycogen, lipids and protein synthe-
sis; inhibition of lipolysis, glycogenolysis and gluconeogene-
sis ; ii) the Ras–MAPK pathway, which regulates the expres-
sion of some genes and cooperates with the PI3K pathway to 
control cell growth and differentiation [1] (Fig. 1). 
In 2010 285 million people worldwide was affected by 
diabetes and this number is estimated to about 400 million in 
2030 [2]. About 95% of diabetic patients suffer from Type 2 
Diabetes Mellitus (T2DM), a form characterized by a defec-
tive insulin signaling in adipose tissue, liver and muscle 
cells. Although the molecular mechanisms leading to the 
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development of T2DM should be still clarified, this phe-
nomenon has been summarized with the term insulin resis-
tance. Genetic background, aging, sedentary, and mostly, 
high caloric uptake and excessive lipids accumulation, are 
considered the main causes favoring the onset of insulin re-
sistance. This is confirmed also by the results of several epi-
demiological analysis that revealed a strict correlation be-
tween insulin resistance and obesity [3-5]. Therapeutic 
treatment of T2DM includes the administration of se-
cretagogues (sulfonylureas) that stimulate insulin release 
from pancreas, -glucosidase inhibitor (acarbose) which re-
duces glucose absorption, biguanides (metformin) and thia-
zolidinediones (pioglitazone and rosiglitazone) that contrib-
ute to reduction of fatty acid deposits and improve insulin 
sensitivity. Nevertheless, all available therapies have limited 
effects and most of the drugs used trigger unexpected side 
effects, forcing patients to discontinue the treatment [6]. The 
lack of effectiveness of current drugs in treating T2DM, the 
high social impact of diabetes as well as the high cost of 
pharmaceutical treatments determine the need to develop 
new therapeutic approaches to prevent the onset and the pro-
gression of this disease. In the last decades, an increasing 
number of studies revealed that many natural substances 
extracted from different organisms (plants, animals, fungi, 
lichens, sponges, chorals, and bacteria) modulate the IR sig-
naling, thereby acting on carbohydrates and/or lipids me-
tabolism [7, 8]. Interestingly, it has been demonstrated that 
also common fruits and vegetables contain several biologi-
cally active components (including polyphenols) able to in-
fluence energetic metabolism and glucose homeostasis, 
without adverse effects. Many scientists suggest that these 
compounds could be used as new drugs to treat T2DM or, 
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Fig. (1). The main pathways of insulin signaling. For acronyms see 'Abbreviations'. 
alternatively, could represent scaffold molecules to obtain 
new and more specific antidiabetic drugs [9, 10]. Dietary 
polyphenols may be useful for supplementary treatments in 
T2DM and its cardiometabolic complications [11-13] inhib-
iting -amylase and -glucosidase in the intestinal lumen, 
thus reducing the absorption of simple sugars [14-16]. Fur-
thermore, some polyphenols may improve glucose uptake in 
muscle and in adipocytes, inhibit gluconeogenesis and pro-
mote the storage of glycogen in the liver. However, the us-
age of these dietary polyphenols as drugs should take into 
account the effects that T2DM may have on their pharma-
cokinetics. Accordingly, an in-depth understanding of diabe-
tes-associated changes in polyphenols absorption, distribu-
tion, metabolism, elimination and bioactivity is needed [17]. 
In this work we review the natural compounds so far de-
scribed to influence the insulin signaling pathway, highlight-
ing their mechanism of action and their efficacy both in vitro
and in vivo models. 
TYPICAL NATURAL COMPOUNDS THAT MAY AF-
FECT INSULIN SIGNALING 
Several human foods such as tea, coffee, wine, cereal 
grains, vegetables, legumes, and fruits contain natural poly-
phenols; that are considered very important for human 
health. Among the 8000 phenolic compounds currently 
known, about half have flavonoid structures. Flavonoids 
(aglycones and their glycosylated derivatives) are the most 
important plant pigments. The basic structure of flavonoid 
aglycones is characterized by a C15 skeleton (Scheme 1)
having a C6-C3-C6 carbon framework which contains a 1-
benzopyran (chromene) ring system, in which the aromatic 
ring is defined as ring A and the pyran as ring C. Another C6 
aromatic ring (B) is linked to the pyran moiety of the 
chromene ring. Flavonoids are further divided into the fol-
lowing subclasses, which differ for oxidation state and con-
nection modality of ring B to the position 2 or 3 of the het-
erocyclic C-ring: flavanones, flavanols, flavones, flavonols 
and isoflavones. Anthocyanidins, and chalchones which con-
tain a 2-phenyl-1-benzopyrazolium, are therefore included in 
the flavonoid class. Chalcones, which lack the C-ring, are 
early intermediates in the biosynthesis of flavonoids in 
which the pyran ring C has not yet been formed. Some 
chemical structure of typical flavonoids are shown in 
Scheme 1. The chemical structures of other typical com-
pounds are shown in Schemes 2-5.
Natural Compounds that Directly Interact and Activate 
Insulin Receptor 
Only few natural compounds, such as demethylasterri-
quinone B1 (also known as L-783,281), 1,2,3,4,6-penta-O-
galloyl--D-glucopyranose, and -lipoic acid, directly act on 
IR, mimicking insulin effects (Fig. 2) [18- 20]. 
Demethylasterriquinone B1 is a metabolite of the fun-
gus species Pseudomassaria sp. that interacts with intracel-
lular IR -subunit stimulating its tyrosine kinase activity 
determinig increased glucose uptake. The action of this 
compound is selective and does not induce insulin-like pro-
liferative effects. Oral subministration of demethylasterri-
quinone B1 to animal models decreases blood glucose level 
without inducing hypoglycaemia, both in streptozotocin-
induced diabetic mice and in lean non-diabetic mice. This 
finding suggests that this compound is able to stimulate IR 
activity or to act as insulin sensitizer, thereby decreasing 
the amount of hormone need to obtain a physiological re-
sponse [21, 22]. 
The 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose is 
an ester of gallic acid with glucose, purified from Lagerstro-
emia speciosa. This compound interacts with the IR -
subunit in a binding site different from that of insulin, induc-
ing a direct IR activation and enhancing glucose transport. 
The 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose elicits 
an insulin-mimetic action in diabetic and obese mice reduc-
ing both blood glucose and insulin levels, with no significant 
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Scheme 1. Chemical structures of the main flavonoid classes, and of typical flavonoids. 
changes in body weight, food intake, or physical activity 
with respect to the control mice [19]. 
Recently, it has been reported that -lipoic acid interacts 
with the tyrosine kinase domain of the insulin receptor, lead-
ing to its autophophorylation and propagation of insulin sig-
naling. Molecular modeling studies on an -lipoic acid-IR 
complex suggest that -lipoic acid stabilizes the active form 
of the IR kinase domain, favoring the ATP binding to the 
kinase domain and contributing to its auto-activation [20]. 
Natural Compound Targeting Phosphotyrosine Protein 
Phosphatase Enzymes 
In physiological conditions insulin signaling is tightly 
regulated by several mechanisms: i) dephosphorylation of 
phospho-tyrosine residues of IR and/or IRS proteins by spe-
cific protein tyrosine phosphatases (PTPs); ii) serine phos-
phorylation of IRS proteins by various Ser/Thr kinases; iii) 
binding of inhibitory proteins; iv) ligand-induced degrada-
tion [1]. It has been demonstrated that hundreds of natural 

























Scheme 2. Competitive inhibitors of PTP1B. Chemical structures: 1, Licoagroaurone; 2, Anhydrofulvic acid; 3, Bakuchiol; 4, (20S)-












































Scheme 3. Non competitive inhibitors of PTP1B. Chemical structures: 1, Hyrtiosal; 2, Amentoflavone; 3, Morolic acid; 4, Trodusquemine; 
5, Psoralidin; 6, Fructigenine A; 7, Ilekudinol B; 8, 16H,17-isovaleryloxy-ent-kauran-19-oic acid. 
substances stimulate insulin signaling acting as inhibitors of 
protein tyrosine phosphatases (Fig. 2), alleviating insulin 
resistance [23], for example: PTP1B [24], LAR (leukocyte 
common antigen-related PTP) [25-29], PTP [30-34], SHP-2 
[35-42], TC-PTP [43, 44], PTP [30, 45], LMW-PTP [46, 
47]; PTP-MEG2 [48]. 
PTP1B is one of the most important negative regulator of 
IR signaling in liver and muscle [49-52]. Hepatic PTP1B 
expression is increased in T2DM rat models [53], while mice 
lacking PTP1B show improved insulin sensitivity with en-
hanced phosphorylation of hepatic insulin receptor and IRS1 
[54]. PTP1B contains an active site loop (P-loop) where the 
phosphate group of the substrate interacts with Arg221 and 
with other P-loop residues, including the catalytic Cys215 
residue. The crystal structure of PTP1B–ligand complexes 
revealed another phosphotyrosine binding site (site B),














































Scheme 4. Mixed type inhibitors of PTP1B. Chemical structures: 1, Ursolic acid; 2, Mulberrofuran G; 3, Licoagrone; 4, Oleanoic acid; 5, 





























Scheme 5. The most potent natural inhibitors of PTP1B. Chemical structures: 1, 7-Oxo-ent-pimara-acid; 2, Aquastatin A; 3, Grecocycline 
B. 
close to the conserved primary active site (site A), which 
contains Met258, Gly259, Gln262, Gln266, Arg24, and 
Arg254 [55]. While competitive inhibitors bind to site A, 
most non competitive and mixed type inhibitors bind to site 
B blocking the catalytic process. Several compounds listed in 
Table 1 have been characterised for their inhibition mecha-
nisms (see below).
Natural PTP1B Inhibitors 
In a detailed review Jiang et al. [56] described about 300 
natural or synthetic products acting as PTP1B inhibitors. 
Tables 1 provides an updated overview of natural substances 
exhibiting PTP1B inhibitory activity on, their IC50 values 
and the natural resources from which they were isolated. 
Most of them have flavonoid or terpenoid structures. About 
15% of flavonoids and almost half of terpenoids listed in 
Tables 1A and 1B, are inhibitors of PTP1B with IC50 values 
in the 2-10 M range. Furthermore, also more than 60 % of 
phenolic compounds listed in Table 1C, and about 40% of 
compounds listed in Table 1D are potent inhibitors of 
PTP1B, with IC50 values in the low M range. About 44% of 
compounds act as a non competitive inhibitors, 34 % as 
mixed-type inhibitors and 22% are competitive inhibitors 
respect to PTP1B (see Scheme 2-4). The compounds 7-Oxo-
ent-pimara-acid, a diterpenoid extracted from Aralia conti-
nentalis (IC50 value = 0.09 M) [57], aquastatin A, a -
galactopyranoside extracted from a Cosmospora species 
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Fig. (2). Inhibition of PTPs by natural compounds improves insulin signaling. Insulin activates the IR tyrosine kinase that phosphorylates 
and recruits different substrate adaptors such as the IRS proteins which, in turn, recruit and activate other effectors contributing to signal 
propagation. Most proteins involved in insulin signaling are regulated by reversible phosphorylation on tyrosine and/or serine/threonine resi-
dues. A number of PTPs act as negative regulators of insulin signaling. One of the most important PTPs involved in the regulation of insulin 
receptor activity is PTP1B, which strongly contributes to downregulation of insulin signaling by dephosphorylating IR and IRS-1. Several 
natural molecules are able to inhibit PTP1B as well as other PTPs, thereby increasing insulin sensitivity. For an explanation of acronyms see 
'Abbreviations'. 
 
(IC50 value = 0.19 M) [58], and Grecocycline B, a benzan-
thracene quinone extracted from a Streptomyces species 
(IC50 value = 0.52 M) [59] (Table 1D) are the most potent 
natural inhibitors of PTP1B (Scheme 5). The majority of the 
compounds analyzed behaves as non competitive and mixed-
type inhibitors. The non competitive inhibitors bind to the 
enzyme at a specific site usually near the active site, distort-
ing the catalytic residues geometry and position. Mixed-type 
inhibitors act similarly, but they also hinder the binding of 
substrate. In silico docking indicated that morin, a non com-
petitive inhibitor of PTP1B, establishes hydrogen bonds with 
residues near to the active site, such as Arg254, Gln262, 
Asp29, Met258 and Gly259 (site B), impairing the ability of 
the enzyme to hydrolyze substrate phosphoesteric bond [60]. 
Docking simulation indicated that site B residues are in-
volved in the binding of ursolic acid, a triterpene contained 
in traditional Chinese medicinal herbs. Ursolic acid, due to 
its different steric hindrance and positioning with respect to 
morin, interacts also with residues at the boundary between a 
site A and site B, thereby influencing substrate binding [61] 
and behaves as a mixed-type inhibitor. Undoubtedly the abil-
ity of ursolic acid to form additional bonds with respect to 
morin, can explain its greater binding affinity. The diterpe-
noid 7-oxo-ent-pimara-8(14),15-diene-19-oic acid, acts as a 
non competitive inhibitor. Nevertheless, it does not interact 
with site B, but with the catalytic WDP loop; this stabilizes 
the open form of the active site, thereby blocking the cata-
lytic process [62]. Few compounds listed in Tables 1A-D 
were tested also on other PTPs. For example ascochitine 
(IC50 value = 38.5 M on PTP1B), extracted from Ascochyta 
salicorniae, is a less potent inhibitor of PTP1B than of M. 
tuberculosis MPtpB (IC50 value = 11.5 M) [63]. Dihydro-
carolic acid (IC50 value = 38 g/ml on PTP1B) and Penitricin 
D (IC50 value = 15.8 g/ml on PTP1B), both extracted from 
Aspergillus niger, are less potent inhibitors versus PTP1B 
than versus the CD45 (IC50 values = 1.2 and 2.3 g/ml, re-
spectively) [64]. Aquastatin A (IC50 value = 0.19 M on 
PTP1B), extracted from a fungus of the Cosmospora species, 
inhibits also TC-PTP, another enzyme involved in negative 
regulation of insulin-mediated signaling [58]; TC-PTP is an 
enzyme highly homologous with PTP1B, displaying 72% 
sequence identity. The compound 7-hydroxy-5,6-dimethoxy-
1,4-phenantrene quinone (IC50 value = 38 M on PTP1B), 
which is a metabolite extracted from Dendrobium monili-
forme, is ten-fold more potent inhibitor against the dual 
specificity VHR PTP than against PTP1B [65]. Corosolic 
acid, a compound contained in several Chinese medicinal 
herbs, inhibits in vitro several diabetes-related non-receptor 
PTPs [66], such as PTP1B (IC50 value = 5.49 M), TC-PTP 
(IC50 value = 11.31 M), SHP1 (IC50 value = 24.56 M) and 
SHP2 (IC50 value = 10.50 M). Shi et al. [66] reported that 
corosolic acid is able to stimulate glucose uptake in cultured 
L6 myotubes. Furthermore, experiments performed with 
GLUT4 transfected CHO/hIR cells showed that corosolic 
acid increases GLUT4 translocation from cytoplasm to the 
cell membrane [66]. Both actions were blocked by wortman-
nin, a specific inhibitor of PI3K, a key downstream enzyme 
of insulin pathway. In addition, corosolic acid induces insu-
lin receptor and Akt-Ser phosphorylation in cultured 
CHO/hIR cells, but it is unable to enhance AMPK phos-
phorylation. These authors suggest that corosolic acid might 
increase glucose uptake and GLUT4 translocation enhancing 
insulin receptor phosphorylation via the inhibition of certain 
PTPs that antagonize IR signaling. Ursolic acid inhibits in
vitro some diabetes-related non-receptor PTPs such as: i) 



































86    Current Medicinal Chemistry, 2015, Vol. 22, No. 1 Paoli et al. 
Table 1A. Natural inhibitors of PTP1B. 
Natural Flavonoids IC50 Structure type Source 
Apigenin 33 M Flavone Apium graveolens, and other plants [60] 
Quercetin 28.12 M Flavonol Ardisia japonica [73] 
8-(1,1-dimethyl-allyl)-5’-(3-methylbut-2-enyl)-3’,4’,5,7-
tetrahydroxyflanvonol
4.3 M Flavonols Broussonetia papyrifera [121] 
3’-(3-methylbut-2-enyl)-3’,4’,7-trihydroxyflavane 41.5 M Flavan Broussonetia papyrifera [121] 
3,3’,4’,5,7-pentahydroxyflavone 23.3 M Flavone Broussonetia papyrifera [121] 
Uralenol 21.5 M Flavones Broussonetia papyrifera [121] 
Broussochalcone A 36.8 M Chalcones Broussonetia papyrifera [121] 
Quercetin-3-O-b-D-glucuronide 7.39 M Flavonol derivative Cyclocarya paliurus [122] 
Myricetin-3-O-b-D-glucuronide 9.47 M Flavonoid derivative Cyclocarya paliurus [122] 
Abyssinoflavone VI 18.9 M Flavanone Erythrina abyssinica [123] 
Abyssinoflavone VII 15.7 M Flavanone Erythrina abyssinica [123] 
Sigmoidin F 14.2 M Flavanone Erythrina abyssinica [123] 
Sigmoidin B 19.4 M Favanone Erythrina abyssinica [123] 
Abyssinin II 17.3 M Flavanone Erythrina abyssinica [123] 
Sigmoidin A 14.4 M Flavanone Erythrina abyssinica [123] 
5-Deoxyabyssinin II 19.2 M Favanone Erythrina abyssinica [123] 
3-Prenylnaringenin 26.7 M Flavanone Erythrina abyssinica [123] 
Abyssinin I 18.2 M Flavanone Erythrina abyssinica [123] 
Abyssinone-VI 20.6 M Chalcone Erythrina abyssinica [123] 
Licoagrochalcone A 16.9 M Chalcone Erythrina abyssinica [123] 
2(S)-5,5',7-trihydroxy-2'-prenyl-(2'',2''-dimethylpyrano)-
(5''6'':3',4')flavanone
13.9 M Flavanone Erythrina abyssinica [124] 
2(S)-5,7-dihydroxy-3'-methoxy-(2''-(5''-hydroxy)-
methylpyrano)-(5'',6'':3',4')flavanone
17.9 M Flavanone Erythrina abyssinica [124] 
2(S)-5,7-dihydroxy-5'-prenyl-(2'2''-(3''-hydroxy)-
dimethylpyrano)-(5'',6'': 3'4')flavanone
14.9 M Flavanone Erythrina abyssinica [124] 
2(S)-5,7-dihydroxy-5'-methoxy-(2'',2''-(3''-hydroxy)-
dimethylpyrano)-(5'',6'':3',4')flavanone
18.2 M Flavanone Erythrina abyssinica [124] 
2(S)-5,7-dihydroxy-5'-prenyl-(2''2''-(3'',4''-dihydroxy)-
dimethylpyrano))-(5'',6'':3',4')flavanone
19.0 M Flavanone Erythrina abyssinica [124] 
2(S)-5,6',7-trihydroxy-5'-prenyl-(2'',2''-dihydroxy)-
dimethylpyrano)-(5'',6'':3',4')flavanone
18.2 M Flavanone Erythrina abyssinica [124] 
Burttinone 18.9 M Flavanone Erythrina abyssinica [124] 
Burttinonedehydrate 21.6 M Flavanone Erythrina abyssinica [124] 
(2S)-5,7-dihydroxy-3-prenyl-2-(4-
hydroxyisopropyl)dihydrofurano (1,3:4,5) flavanone
15.2 M Flavanone Erythrina abyssinica [125] 
(2S)-5,7-dihydroxy-3-methoxy-2-(4-
hydroxyisopropyl)dihydrofurano (1,3:4,5)flavanone
16.1 M Flavanone Erythrina abyssinica [125] 
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(Table 1A) contd…. 








18.3 M Flavanone Erythrina abyssinica [125] 
Erylatissin C 16.2 M Flavanone Erythrina abyssinica [125] 
Abyssinin III 19.6 M Flavanone Erythrina abyssinica [125] 
Erythribyssin E 15.2 M Isoflavanones Erythrina abyssinica [126] 
5-Deoxyabyssinin II 19.2 M 5-Deoxyflavonoid deriv Erythrina abyssinica [126] 
7-hydroxy-2-(4-methoxy-3-(3-methylbut-2-
enyl)phenyl)chroman-4-one
16.5 M 5-Deoxyflavonoid deriv Erythrina abyssinica [126] 
Abyssinones V 22.6 M 5-Deoxyflavonoid deriv Erythrina abyssinica [126] 
Abyssinone II 29.2 M 5-Deoxyflavonoid deriv Erythrina abyssinica [126] 
Prostratol C 17.2 M 5-Deoxyflavonoid deriv Erythrina abyssinica [126] 
Erythribyssin G 35.8 M Prenylated flavanone Erythrina abyssinica [126] 
Erythribyssin J 14.9 M Isoflavanones Erythrina abyssinica [126] 
Erythribyssin A 19.3 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Neorautenol 7.6 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Erybreadin B 4.2 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
3,9-Dihydroxy-4-prenyl-(6aR;11aR) pterocarpan 19.5 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Folitenol 7.8 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Erybreadin D 6.4 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Erysubin E 8.8 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
Erybreadin C 7.3 M Pterocarpans (Isoflavone der) Erythrina abyssinica [127] 
5,2,4-trihydroxy-6-(,-dimethylallyl)-2,2-
dimethyldihydropyrano(5,6) isoflavanone
4.1 M Isoflavanone Erythrina addisoniae [128] 
Orientanol E 10.1 M Prenylated isoflavonoid Erythrina addisoniae [128] 
Warangalone 42.5 M Prenylated isoflavonoid Erythrina addisoniae [128] 
2,3-Dihydroauriculatin 2.6 M Prenylated isoflavonoid Erythrina addisoniae [128] 
Erylysin A 14.8 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Erylysin B 6.0 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Isoneorautenol 18.1 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Phaseollin 5.1 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Orientanol C 8.2 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Erysubin D 9.7 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Eryvarin D 4.1 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Calopocarpin 7.6 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
Erybraedin A 1.01 g/ml Pterocarpans (Isoflavone der) Erythrina lysistemon Hutch [129] 
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Natural Flavonoids IC50 Structure type Source 
Abyssinone-V-4-O-methyl ether 26.3 M Flavonoid Erythrina mildbraedii [130] 
Abyssinone-IV-4-O-methyl ether 21.2 M Isoprenylated Flavonoid Erythrina mildbraedii [130] 
Abyssinone-V 39.7 M Flavonoid Erythrina mildbraedii [130] 
Abyssinone-IV 16.0 M Flavonoid Erythrina mildbraedii [130] 
Abyssinone-VI-4-O-methyl ether 14.8 M Chalcone (isoprenylated Flavonoid Erythrina mildbraedii [130] 
Sigmoidin E 39.2 M Flavonoid Erythrina mildbraedii [130] 
Alpinumisoflavone 41.5 M Isoflavone Erythrina mildbraedii [130] 
Licoflavanone-4'-O-methyl ether 29.6 M flavanone Erythrina mildbraedii [131] 
2',7-dihydroxy-4'-methoxy-5'-(3-methylbut-2-
enyl)isoflavone
21.3 M Isoflavone Erythrina mildbraedii [131] 
(3R)-2',7-dihydroxy-3'-(3-methylbut-2-enyl)-2''',2'''-
dimethylpyrano(5''',6''' : 4 ',5' )isoflavan
5.5 M Isoflavan Erythrina mildbraedii [131] 
Abyssinin II 40.5 M Flavanone Erythrina mildbraedii [131] 
Parvisoflavone B 42.6 M Isoflavone Erythrina mildbraedii [131] 
Licoagrone 6.0 M Flavonoid dimer Glycyrrhiza species [132] 
Licoagrodin 11.5 M Flavonoid dimer Glycyrrhiza species [132]
Licoagroaurone 23.9 M Prenylated aurone Glycyrrhiza species [132]
Isobavachalcone 27.3 M Prenylated chalcone Glycyrrhiza species [132]
Glisoflavone 27.9 M Flavones Glycyrrhiza uralensis [133] 
Kuwanon J 2.7 M Chalcone derivative Morus bombycis [134] 
Kuwanon R 8.2 M Chalcone derivative Morus bombycis [134] 
Kuwanon V 13.8 M Chalcone derivative Morus bombycis [134] 
Licochalcone A 19.1 M Retrochalcone Morus bombycis [134] 
Licochalcone C 30.9 M Retrochalcone Morus bombycis [134] 
Licochalcone E 20.7 M Retrochalcone Morus bombycis [134] 
Karanjin 84.5 M Flavonoid (benzopyran dervative) Pongamia pinnata [85] 
Morin 15 M Flavonol Psidium guajava, and other plants [60] 
Amentoflavone 7.3 M Flavone Selaginella tamariscina [77] 
3',5'-Diprenylgenistein 31.75 M Flavonoid (genistein derv) Tetracera scandens [78] 
6,8-Diprenylgenistein 28.13 M Flavonoid (genistein derv) Tetracera scandens [78] 
Derrone 20.63 M Flavonoid (genistein derv) Tetracera scandens [78] 
Alpinumisoflavone 37.52 M Flavonoid (genistein derv) Tetracera scandens [78] 
OTHER NATURAL BENZOPYRAN DERIVATIVES   
Ascochitine 38.5 M Benzopyran derivative Ascochyta salicorniae [63] 
Sanggenon C 2.6 M Benzopyran derivative Morus [135] 
Sanggenon G 1.6 M Benzopyran derivative Morus [135] 
Mulberrofuran C 4.9 M Benzopyran derivative Morus [135] 
Kuwanon L 16.9 M Benzopyran derivative Morus [135] 
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Anhydrofulvic acid 1.90 M Benzopyran derivative Penicillium sp [136] 
Phelligridin H 3.1 M Benzopyran derivative Phellinus igniarius [137] 
Phelligridin I 3.0 M Benzopyran derivative Phellinus igniarius [137] 
Psoralidin 9.4 M benzopyran derivative Psoralea corylifolia [138] 
Psoralidin 9.4 M Benzopyran derivative Psoralea corylifolia [138] 
NATURAL BENZOFURAN DERIVATIVES   
2-(2',4'-dihydroxy-3'-(3-methylbut-2-enyl)phenyl)-6-
hydroxybenzofuran
13.6 M Benzofuran derivative Erythrina addisoniae [139] 
2-(2'-methoxy-4'-hydroxy-5'-(3-methylbut-2-
enyl)phenyl)-6-hydroxybenzofuran
17.5 M Benzofuran derivative Erythrina addisoniae [139] 
2-(2'-methoxy-4'-hydroxyphenyl)-5-(3-methylbut-2-
enyl)-6-hydroxybenzofuran
15.7 M Benzofuran derivative Erythrina addisoniae [139] 
Glycybenzofuran 25.5 M Benzofuran dervative) Glycyrrhiza uralensis] [133] 
Albafuran A 9.2 M 2-arylbenzofuran Morus bombici [134] 
Mulberrofuran W 2.7 M 2-arylbenzofuran Morus bombici [134] 
Mulberrofuran D 4.3 M 2-arylbenzofuran Morus bombici [134] 
Pongamol 75.0 M Benzofuran dervative) Pongamia pinnata [85] 
Usimine A 15.0 M Benzofuran derivative Stereocaulon alpinum [140] 
Usimine B 27.7 M Benzofuran derivative Stereocaulon alpinum [140] 
Usimine C 23.2 M Benzofuran derivative Stereocaulon alpinum [140] 
Usnic acid 16.4 M Benzofuran derivative Stereocaulon alpinum [140] 
Table 1B. Natural inhibitors of PTP1B. 
Natural Terpenoids IC50 Structure Type Sources 
Acanthoic acid 23.5 M Diterpenoid Acanthopanax koreanum [141] 
ent-kaur-16-en-19-oic acid 20.2 M Diterpenoid Acanthopanax koreanum [141] 
16aH,17-isovaleryloxy-ent-kauran-19-oic acid 7.1 M Diterpenoid Acanthopanax koreanum [141] 
Continentalic acid 0.66 M Diterpenoid Aralia continentalis [57] 
Kaurenoic acid 4.64 M Diterpenoid Aralia continentalis [57] 
ent-Pimarol 9.85 M Diterpenoid Aralia continentalis [57] 
7-Oxo-ent-pimara- acid 0.09 M Diterpenoid Aralia continentalis [57] 
16-Hydroxy-17-isovaleryloxy-ent-kauran 19-oic acid 1.51 M Diterpenoid Aralia continentalis [57] 
17-Hydroxy-ent-kaur-15-en-19-oic acid 9.12 M Diterpenoid Aralia continentalis [57] 
15,16-Epoxy-17-Hydroxy-ent-kauran-19-oic acid 1.96 M Diterpenoid Aralia continentalis [57] 
16 16,17-Dihydroxy-ent-kauran-19-oic acid 0.56 M Diterpenoid Aralia continentalis [57] 
ent-Thermarol 1.34 M Diterpenoid Aralia continentalis [57] 
4-Epiruilopezol 10.98 M Diterpenoid Aralia continentalis [57] 
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ent-pimara-8(14),15-diene-19-oic acid (continentalic acid) 2.85 M Diterpenoids Aralia continentalis [62] 
7-oxo-ent-pimara-8(14),15-diene-19-oic acid 2.60 M Diterpenoids Aralia continentalis [62] 
ent-pimara-8(14),15-diene-19-ol (ent-pimarol) 12.95 M Diterpenoids Aralia continentalis [62] 
8a-hydroxy-ent-pimara-15-en-19-ol (ent-thermarol) 7.06 M Diterpenoids Aralia continentalis [62] 
ent-kaur-16-en-19-oic-acid (kaurenoic acid 8.27 M Diterpenoids Aralia continentalis [62] 
3-Oxoolean-12-en-27-oic acid 6.8 M Triterpene Astilbe koreana [142] 
3b-Hydroxyolean-12-en-27-oic acid (b-peltoboy-kinolic 
acid
5.2 M Triterpene Astilbe koreana [142] 
3b-Hydroxyurs-12-en-27-oic acid 4.9 M Triterpene Astilbe koreana [142] 
3a,24-Dihydroxyolean-12-en-27-oic acid 11.7 M Triterpene Astilbe koreana [142] 
3b,6b-Dihydroxyolean-12-en-27-oic acid (astilbic acid) 12.8 M Triterpene Astilbe koreana [142] 
11-keto boswellic acid 8.04 M Triterpene Boswellia carteri [71] 
Oleanolic acid 3.37 M Triterpene Calendula. officinalis [71] 
Ursolic acid 3.08 M Triterpenoids Calendula. officinalis [71] 
Corosolic acid 5.49 M Triterpenoids Calendula. officinalis [71] 
Madecassic acid 12.38 M Triterpene Centella asiatica [71] 
Ursolic acid 3.08 M Triterpenoids Cornus officinalis [67] 
O-Methyl nakafuran-8 lactone 1.58 M Sesquiterpenoid Dysidea sp [143] 
Hydroxybutenolide 8.8 g/mL Sesquiterpene Dysidea septosa [144] 
Microcionin-4 11.6 g/mL Sesquiterpene Dysidea septosa [144] 
dihydropallescensin-2 6.8 g/mL Sesquiterpene Dysidea septosa [144] 
Nakafuran-8 1.9 g/mL Sesquiterpenoid Dysidea septosa [144] 
Dysidine 6.70 M Sesquiterpene Dysidea villosa [145] 
21-Dehydroxybolinaquinone 39.50 M Sesquiterpene quinone Dysidea villosa [145] 
Betulin 15.3 M Triterpene Euphorbia micractina [72] 
(23S)-3b,20z,21z-trihydroxy-19-oxo-21,23-
epoxydammarane-24-ene
19.3 M Triterpene Gynostemma pentaphyllum [146] 
(20S,24S)-3b,12b,20,24-epoxydammarane-25-triol 20.4 M Triterpene Gynostemma pentaphyllum [146] 
(20S,24S)-3b,12b,20,24-epoxy-12,25-dihydroxydammarane 21.7 M Triterpene Gynostemma pentaphyllum [146] 
(20S),3b,21-trihydroxy-25-methoxydammarane-23-ene 25.1 M Triterpene Gynostemma pentaphyllum [146] 
(20S)-3b,12b,12,25-dihydroxydammar-23-ene 28.5 M Triterpene Gynostemma pentaphyllum [146] 
(20S)-3b,20,23e-trihydroxydammarane-24-en-21-oic acid-
21,23 lactone
5.3 M Triterpene Gynostemma pentaphyllum [146] 
(20R)-3b,20,23e-trihydroxydammarane-24-en-21-oic acid-
21,23 lactone
5.7 M Triterpene Gynostemma pentaphyllum [146] 
Hueafuranoid A 13.9 M Diterpene furanoid Huea sp [147] 
Hyrtiosal 42 M Sesterterpenoid Hyrtios erectus [86] 
Sulfircin 29.8 M Sesterterpene Ircinia [148] 
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 (3b,6b,8a,10b)-3-acetyl-6,8,10-trihydroxyeremophil-7(11)-
eno-12,8-lactone
1.34 M Sesquiterpene Ligularia fischeri [149] 
Oleanolic acid 3.4 M Triterpene Phoradendron reichenbachianum (AEPr) [61]
Moronic acid 13.2 M Triterpene Phoradendron reichenbachianum (AEPr) [61]
Morolic acid 9.1 M Triterpene Phoradendron reichenbachianum (AEPr) [61]
Ursolic acid 2.3 M Triterpene Phoradendron reichenbachianum (AEPr) [61]
Lipidyl pseudopterane A 71 g/mL Diterpene Pseudopterogorgia acerosa [150] 




Sesquiterpenoid Psidium guajava L [151] 
Rhododendric acid A 6.3 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
Ursolic acid 3.1 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
Corosolic acid 7.0 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
Rotundic acid 20.1 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
2a,3a,23-trihydroxyursa-12,20(30)-dien-28-oic acid 17.4 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
23-hydroxyursolic acid 7.4 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
Actinidic acid 18.0 M Triterpenoids Rhododendron brachycarpum G. Don [70] 
Isotanshinone IIA 11.4 M Diterpene Salvia miltiorrhiza [152] 
Dihydroisotanshinone I 22.4 M Diterpene Salvia miltiorrhiza [152] 
Sarcophytonolide N 5.95 M Diterpenoid Sarcophyton trocheliophorum [153] 
Sarcrassin E 6.33 M Diterpenoid Sarcophyton trocheliophorum [153] 
4Z,12Z,14E-Sarcophytolide 15.4 M Diterpenoid Sarcophyton trocheliophorum [153] 
Cembrene-C 26.6 M Diterpenoid Sarcophyton trocheliophorum [153] 
Chetoemblide 27.2 M Diterpenoid Sarcophyton trocheliophorum [153] 
Sarcotroate B 6.97 M Diterpenoids Sarcophyton trocheliophorum [74] 
Mokko lactone 1.4 g/mL Sesquiterpene Saussurea lappa [154] 
Dehydrocostuslactone 6.5 g/mL Sesquiterpene Saussurea lappa [154] 
Betulinic acid 0.7 g/mL Triterpenoid Saussurea lappa [154] 
Betulinic acid methyl ester 0.9 g/mL Triterpenoid Saussurea lappa [154] 
ent-16betaH, 17-isobutyryloxy-kauran-19-oic acid 8.7 M Diterpene Siegesbeckia glabrescens [155] 
ent-16betaH, 17-acetoxy-18-isobutyryloxy-kauran-19-oic 
acid
30.6 M Diterpene Siegesbeckia glabrescens [155] 
ent-16betaH, 17-isobutyryloxy-kauran-19-oic acid 8.07 M Diterpene Siegesbeckia glabrescens [155] 
ent-16betaH, 17-acetoxy-18-isobutyryloxy-kauran-19-oic 
acid
30.6 M Diterpene Siegesbeckia glabrescens [155] 
Lupenone 13.07 M Triterpene Sorbus commixta [156] 
Lupeol 5.06 M Triterpene Sorbus commixta [156] 
3-Acetoxy-28-hydroxyolean-12-ene 44.4 M Triterpenoid Styrax japonica [157] 
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3-Acetoxyolean-12-en-28-acid 7.8 M Triterpenoid Styrax japonica [157] 
3-Acetoxyolean-12-en-28-aldehyde 9.3 M Triterpenoid Styrax japonica [157] 
3-Hydroxyolean-12-en-28-oic acid 5.2 M Triterpenoid Styrax japonica [157] 
Glycyrrhetic acid 13.8 M Ttriterpenoid Styrax japonica [157] 
Ursolic acid 3.8 M Triterpene Symplocos paniculata [68] 
Corosolic acid 7.2 M Triterpene Symplocos pani culata [68] 
Ilekudinol A 29.1 M Triterpene Weigela subsessilis [158] 
Ilekudinol B 5.3 M Triterpene Weigela subsessilis [158] 
Corosolic acid 5.49 M Triterpene Several traditional Chinese medicinal herbs [66]
Table 1C. Natural inhibitors of PTP1B. 
Compound IC50 Structure Type Source 
Caffeic acid 3.06 M Cnnamic acid derivative Artemisia minor [159] 
Compound 1 3.7 M Vanillic acid derivative Cladophora socialis [160] 
Compound 2 1.7 M Vanillic acid derivative Cladophora socialis [160] 
Curcumin
In vivo PTP1B 
inhibitor 
Phenol derivative Curcuma longa [79] 
Cyclospirolide 16.64 M Phenol derivative Cyclocarya paliurus [122] 
Caffeic acid 1,92 M Cinnamic acid derivative Cyclocarya paliurus [122] 
1,2,3,4,6-penta-O-galloyl-D-glucopyranose 4.8 M Gallic acid derivative Paeonia lactiflora [75] 
3,4-dihydroxy benzoic acid 52.9 M Benzoic acid derivative Phellinus linteus [161] 
Bakuchiol 20.8 M Phenol derivative Psoralea corylifolia [138] 
2,2, 3,3-tetrabromo-4,4,5,5-tetrahydroxydiphenyl
methane
2.4 M Bromophenol derivative Rhodomela confervoides [162] 
3-bormo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)
pyrocatechol
1.7 M Bromophenol derivative Rhodomela confervoides [162] 
bis(2,3-dibromo-4,5-dihydroxybenzyl) ether 1.5 M Bromophenol derivative Rhodomela confervoides [162] 
2,2,3-tribromo-3,4,4,5-tetrahydroxy-6-
ethyloxymethyldiphenylmethane
0.84 M Bromophenol derivative Rhodomela confervoides [162] 
3, 4-dibromo-5-(methoxymethyl)-1, 2-benzenediol 3.4 M Bromophenol derivative Rhodomela confervoides and Leathesia nana [163] 
2-methyl-3-(2, 3-dibromo4, 5-dihydroxy)-
propylaldehyde
4.5 M Bromophenol derivative Rhodomela confervoides and Leathesia nana [163] 
3-(2, 3-dibromo-4, 5-dihydroxy-phenyl)-4-bromo-5,
6-dihydroxy-1, 3-dihydroiso-benzofuran
2.8 M Bromophenol derivative Rhodomela confervoides and Leathesia nana [163] 
2,3-dibromo-4,5-dihydroxybenzyl methyl ether 39.0 M Bromophenol derivative Symphyocladia latiuscula [164] 
2,3,6-tribromo-4,5-dihydroxybenzaldehyde 19.4 M Bromophenol derivative Symphyocladia latiuscula [164] 
2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether 3.9 M Bromophenol derivative Symphyocladia latiuscula [164] 
bis(2,3,6-tribromo-4,5-dihydroxyphenyl)methane 4.3 M Bromophenol derivative Symphyocladia latiuscula [164] 
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1,2-bis(2,3,6-tribromo-4,5-dihydroxyphenyl)-ethane 3.5 M Bromophenol derivative Symphyocladia latiuscula [164] 
1-(2,3,6-tribromo-4,5-dihydroxybenzyl)-pyrrolidin-
2-one
25.6 M Bromophenol derivative Symphyocladia latiuscula [164] 
Gyrophoric acid 3.6 M Benzoic acid derivative Umbilicaria antartica [165] 
lecanoric acid 31 M Benzoic acid derivative Umbilicaria antartica [165] 
Table 1D. Natural inhibitors of PTP1B. 
Compound IC50 Structure Type Sources 
Maesanin 4.56 M Benzoquinone derivative Ardisia japonica [166] 
2,5-dihydroxy-3-((10Z)-pentadec-10-en-1-
yl)(1,4)benzoquinone)
19.15 M Benzoquinone derivative Ardisia japonica [166] 
5-ethoxy-2-hydroxy-3-((10Z)-pentadec-10-en-1-
yl)(1,4)benzoquinone
3.55 M Benzoquinone derivative Ardisia japonica [166] 
5-ethoxy-2-hydroxy-3-((8Z)-tridec-8-en-1-
yl)(1,4)benzoquinone
3.01 M Benzoquinone derivative Ardisia japonica [166] 
7-hydroxy-5,6-dimethoxy-1,4-
phenanthrenequinone
38.0 M Phenanthrene derivative Dendrobium moniliforme [65] 
Grecocycline B 0.52 M Benzanthracene quinone Streptomyces sp. Acta 1362 [59] 
Cyclonoside A 2.11 M Naphtoquinone derivative Cyclocarya paliurus [122] 
5-hydroxynaphthalene-1,4-di-O-b-D-
glucopyranoside
10.90 M Naphtalene derivative Cyclocarya paliurus [122] 
Nocardione A 14.0 M Naphto-furan-dione Nocardia sp. TP-A0248 [167] 
Ohioensins F 3.5 M Xanthene derivative Polytrichastrum alpinum [168] 
Ohioensins G 5.6 M Xanthene derivative Polytrichastrum alpinum [168] 
ohioensins A 4.3 M Benzonaphthoxanthenone Polytrichastrum alpinum [168] 
ohioensins C 7.6 M Benzonaphthoxanthenone Polytrichastrum alpinum [168] 
Berberine Ki = 91.3 nM Isoquinoline alkaloids Several plants [82] 
Papaverine 1.20 M Opium alkaloid Papaver somniferum [81] 
Caulerpin 3.77 M Indole derivative Caulerpa taxifolia [169] 




Penicillium spp. and Eurotium sp. [170] 
Viridicatol 64 M Quinoline derivative Penicillium spp. and Eurotium sp. [170] 
Echinulin 29.4 M Diketopiperazin Penicillium spp. and Eurotium sp. [170] 
Ceramide 25.1 M Sfingosine derivative Polyporus umbellatus [171] 
KS-506a 4.9 M
Polyphenol containing an S-S 
bond
Micromucor ramannianus var. angulisporus b [172] 
Piceamycin 10.1 M Polyketide antibiotic Streptomyces sp. GB 4-2 [173] 
Gymnorrhizol 14.9 M Macrocyclic polydisulfide Bruguiera gymnorrhiza [174] 
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Bruguiesulfurol 17.6 M Cyclic disulfides Bruguiera gymnorrhiza [175] 
Falcarindiol 9.15 M Fatty alcohol Aegiceras corniculatum [176] 
Flavoglaucin 13.4 M Benzaldehyde derivative Penicillium spp. and Eurotium sp. [170] 
3’,5’,6’,6-tetrabromo-2,4-dimethyldiphenyl ether 2.97 M Benzene derivative Laurencia similis [177] 
2’,5’,6’,5,6-pentabromo-3’,4’,3,4-
tetramethoxybenzo-phenone
2.66 M Benzene derivative Laurencia similis [177] 
Woodylide C 4.7 mg/mL Polyketide Plakortis simplex [178] 
Hippolide A 23.81 M Acylic manoalide derivative Hippospongia lachne [179] 
Hippolide B 39.67 M Acylic manoalide derivative Hippospongia lachne [179] 
Manzamenone B 10.8 M Fatty acid derivatives Plakortis (unknown species) [180] 
Manzamenone E 13.5 M Fatty acid derivatives Plakortis (unknown species [180] 
Albidopyrone 128 g/mL Pyrone derivative Streptomyces sp. NTK 227 [181] 
3-Hexadecanoyl-5-hydroxymethyl tetronic acid 
(RK-682)
4.5 M Furandione derivative Streptomyces [135] 
Lobaric acid 0.87 M Depsidone-type Stereocaulon alpinum [182] 
Pseudodepsidone-type compound 2 6.86 M Pseudodepsidone-type Stereocaulon alpinum [182] 
Pseudodepsidone-type compound 3 2.48 M Pseudodepsidone-type Stereocaulon alpinum [182] 
Stereocalpin 40 M cyclic Depsipeptide Stereocaulon alpinum [182] 
Aquastatin A 0.19 M -Galactopyranoside Cosmospora sp. SF-5060 [58] 
Episesamin 2,6-dicatechol 21.86 M Lignan derivative Morinda citrifolia [69] 
()-Pinoresinol 18.69 M Lignan derivative Morinda citrifolia [69] 
Lirioresinol B 15.01 M Lignan derivative Morinda citrifolia [69] 
Lirioresinol B dimethyl ether 16.82 M Lignan derivative Morinda citrifolia [69] 
meso-dihydroguaiaretic acid 19.6 M Lignan derivative Myristica fragrans [183] 
Otobaphenol 48.9 M Lignan derivative Myristica fragrans [183] 
Ratanhiaphenol III 20.2 M Lignan derivative Krameria lappacea [76] 
(7R,8R)-3-methoxy-1-carboxy-4,7-epoxy-8,3-
oxyneolignan-4,9-diol
19.56 M Neolignan Morinda citrifolia [69] 
(Z)-aglawone 1.12 g/mL Steroid Toona ciliata var. pubescens [184] 
Trodusquemine 1 M Aminosterol Squalus acanthias [87], [185 ] 
(2S,3S,4R,2'R)-2-(2'-hydroxytricosanoylamino)-
nonadecane-1,3,4-triol
25.1 g/mL Steroids Polyporus umbellatus [171] 
19-norergosta-5,7,9,22-tetraene-3-ol 8.9 g/mL Steroids Polyporus umbellatus [171] 
24-ethylcholesta-7,22-diene-3,5,6-triol 6.5 g/mL Steroids Polyporus umbellatus [171] 
24-methylcholesta-7,22-diene-3,5,6-triol 7.5 g/mL Steroids Polyporus umbellatus [171] 
Penstyrylpyrone 5.28 Pyrone derivative Penicillium sp [136] 
Dihydrocarolic acid 38 g/mL Furan derivative Aspergillus niger [64] 
Penitricin D 15.8 g/mL Cyclopropan derivative Aspergillus niger [64] 
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IC50 = 3.08 M [67], IC50 = 3.8 M [68], IC50 = 4.12 M 
[69], IC50 = 3.1 M [70], IC50 = 2.3 M [61]; ii) TC-PTP 
IC50 value = 3.33 M [67]; iii) SHP2 (IC50 value = 2.73 M) 
[67]; iv) LAR (IC50 value = 3.8 M) [61]. Furthermore, urso-
lic acid enhances insulin receptor phosphorylation in 
CHO/hIR cells and stimulates glucose uptake in L6 myo-
tubes [67]. In addition this compound shows signicant an-
tidiabetic activity in Streptozotocin-nicotinamide diabetic 
rats [61]. Oleanolic acid, a triterpene contained in traditional 
Chinese medicinal herbs [71], is another PTP1B inhibitor 
(IC50 value = 9.5 M [61]; 4.2 M [72]; 23.9 M [73]; 3.37 
M [71]; 2.56 M [74]). Oleanolic acid is active in vivo, 
showing a moderate antidiabetic activity in Streptozotocin-
nicotinamide diabetic rats [61]. The lignans episesamin 2,6-
dicatechol (IC50 value = 21.86 M on PTP1B), lirioresinol B 
(IC50 value = 15.01 M), and lirioresinol B dimethyl ether 
(IC50 value = 16.82 M), extracted from Morinda citrifolia 
[69], show a strong stimulatory action on 2-NBDG uptake in 
3T3-L1 adipocyte cells. The compound 1,2,3,4,6-penta-O-
galloyl-D-glucopyranose (IC50 value = 4.8 M on PTP1B) 
acts as an insulin sensitizer in human hepatoma cells [75]. 
The lignan ratanhiaphenol III (IC50 value = 20.2 M on 
PTP1B) is able to increase IR phosphorylation as well as 
glucose uptake stimulated by insulin in cultured myotubes 
[76]. The treatment of 32D cells overexpressing the IR with 
amentoavone, a non competititve inhibitor of PTP1B (IC50 
value = 7.3 M) extracted from Selaginella tamariscina, 
induces a dose-dependent increase in IR tyrosine phosphory-
lation [77]. The PTP1B inhibitors 3’,5’-diprenylgenistein 
(IC50 value = 31.75 M), 6,8-diprenylgenistein (IC50 value = 
28.13 M), derrone (IC50 value = 20.63 M) and alpinu-
misoavone (IC50 value = 37.52 M), extracted from Tetrac-
era scandens, exhibit a signicant glucose-uptake activity in 
basal and insulin-stimulated L6 myotubes [78]. The flavonol 
Morin, a non-competitive inhibitor of PTP1B (IC50 value = 
15 M), inhibits also other two enzymes that antagonize IR 
signaling, i.e. TC-PTP (IC50 value = 19.1 M) and LMW-
PTP (IC50 value = 36.4 M). Morin is able to increase IR and 
Akt phosphorylation as well as to inhibit gluconeogenesis 
and to enhance glycogen synthesis in HepG2 cells [60]. The 
action of morin is selective for the insulin signaling, since it 
is unable to stimulate phosphorylation of other tyrosine 
kinase receptors such as EGFR and PDGFR. Curcumin, 
which is a phenolic compound extracted from Curcuma 
longa, produces a number of biological actions being a 
PTP1B inhibitor in vivo. In fact, in fructose-fed rats it is able: 
i) to reduce serum insulin and leptin levels; ii) to increase 
phosphorylation of insulin receptor and IRS-1 enhancing Akt 
and ERK1/2 activation in the liver; iii) to increase phos-
phorylation of hepatic janus-activated kinase-signal trans-
ducer 2 and subsequently to stimulate activation of Akt and 
ERK1/2 [79]. Fructose decreases tyrosine phosphorylation of 
IRS1 and inhibits activation of Akt and extracellular signal-
regulated kinase 1/2 (ERK1/2) in peripheral tissues of rats 
[80]. Papaverine, which is an opium alkaloid contained in 
Papaver somniferum, is a strong PTP1B inhibitor (IC50 = 
1.20 M). In vivo, papaverine signicantly decreases fasting 
blood glucose level of Balb/c mice [81]. Berberine, an alka-
loid contained in several plant species, mimics insulin action 
by increasing glucose uptake in 3T3-L1 adipocytes and L6 
myocytes inhibiting the phosphatase activity of PTP1B (Ki 
value (competitive) = 91.3 nM) [82] and increasing the 
phosphorylation of IR, IRS1 and Akt. Furthermore, berber-
ine lowers hyperglycaemia and improves impaired glucose 
tolerance in diabetic mice [83], as well as elicits antidiabetic 
effects in clinical trials [84]. The compounds pongamol and 
karanjin, extracted from Pongamia pinnata fruits, exert a 
moderate but signicant inhibitory effect on PTP1B; in addi-
tion they are able to decrease blood glucose levels both in 
streptozotocin-induced diabetic rats and in db/db mice [85]. 
Moronic acid and morolic acid, two terpenic acids extracted 
from Phoradendron reichenbachianum and from other 
plants, are able to induce a signicant decrease in plasma 
glucose concentration in streptozotocin-nicotinamide dia-
betic rats. Moronic acid is a mixed type inhibitor of PTP1B 
displaying an IC50 value of 13.2 M, whereas morolic acid is 
a non-competitive inhibitor of PTP1B displaying and IC50 
value of 9.1 M [61]. Hyrtiosal, extracted from the marine 
sponge Hyrtios erectus, is a non competitive inhibitor of 
PTP1B (IC50 = 42 M) that displays potent activity in abol-
ishing the retardation of AKT membrane translocation 
caused by PTP1B overexpression in CHO cells. Furthermore 
hyrtiosal dramatically enhances the membrane translocation 
of GLUT4 in PTP1B-overexpressed CHO cells [86]. The 
aminosterol trodusquemine is a potent allosteric non com-
petitive inhibitor of PTP1B. Trodusquemine’s inhibition is 
highly selective for PTP1B, since its IC50 value (224 M) for 
TC-PTP (70% sequence identity with PTP1B) was approxi-
mately two logs less than that against PTP1B (1M). This 
compound, isolated from the liver of the dogfish shark Squa-
lus acanthias, is able to inhibit PTP1B activity in HepG2 
cells, resulting more potent than orthovanadate, a well 
known non specific tyrosine phosphatase inhibitor [87]. 
Lantz et al. [87] reported that in HepG2 cells trodusquemine 
enhances insulin-induced tyrosine phosphorylation of IR 
about three-fold, whereas trodusquemine by itself (in the 
absence of insulin) had no effect. Trodusqueamine acts also 
in vivo both on central and peripheral tissues displaying a 
very interesting insulin sensitizing activity. In fact, tro-
dusquemine-treated rats show an approximately twofold in-
crease in insulin-induced tyrosine phosphorylation of hypo-
thalamic IR and a 5.4-fold increase in phosphorylation of 
STAT3, a downstream transcription factor. Trodusquemine 
itself has no effect on tyrosine phosphorylation of IR but 
induces a 2.7-fold increase of STAT3 phosphorylation in 
hypothalamus. Furthermore systemic administration of tro-
dusquemine in mice results in enhanced insulin-induced 
phosphorylation of IRS1 andAkt in the liver, demonstrating 
its peripheral activity [88]. 
Natural Substances that Increase Glucose Uptake Acting 
Through the AMPK Activation 
Compelling evidences suggest that in most cases anti-
hyperglycaemic effects of natural compounds are mediated 
by AMPK, the same molecular target of metformin [89]. 
Therefore, several of these natural compounds could be used 
to treat T2DM or as scaffold structures to design and synthe-
size more potent and selective drugs. AMPK is a key player 
in the response to a variety of metabolic stresses and it is 
directly involved in the regulation of GLUT4 trafficking on 
the plasma membrane [90] (Fig. 3). Unlike insulin, AMPK is 
activated in response to stress conditions or stimuli that 
cause a decrease of ATP levels such as physical activity, 
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Fig. (3). Two signaling pathways involved in the regulation of GLUT4 translocation onto the plasma membrane. AKT and AMPK 
phosphorylate AS160 on multiple phosphorylation sites. AS160, which contains a Rab-GAP domain, is a key protein responsible for GLUT4 
translocation onto plasma membrane. In insulin-sensitive cells and in the absence of hormone or stress stimuli (such as nutrient starvation or 
muscle contraction), Rab-GTP proteins interact with AS160; in turn, the AS160-Rab-GTP complex interacts with GLUT4 storage vesicles. 
Non-phosphorylated AS160 stimulates the GTPase activity of the Rab proteins which are converted in their inactive state (Rab-GDP). 
AS160-Rab-GDP forms a stable complex with GLUT4 storage vesicles but is unable to stimulate actin remodelling, an essential event to 
trigger GLUT4 vesicles translocation onto the plasma membrane. On the contrary, insulin or AMPK-mediated phosphorylation of AS160 
inhibits the Rab-GAP GTPase activity, thereby eliciting accumulation of Rab-GTP. Consequently, AS160-Rab-GTP complex dissociates
from GLUT4 storage vesicles, promoting actin remodeling and translocation of GLUT4 onto the plasma membrane. For an explanation of 
acronyms see 'Abbreviations'. 
nutrients deprivation or the presence of metabolic inhibitors. 
High rate of ATP consumption contribute to increase intra-
cellular levels of AMP, a potent positive allosteric effector of 
AMPK. Once activated, AMPK phosphorylates several key 
enzymes involved in the metabolic regulation, inhibiting the 
synthesis of macromolecules and stimulating catabolic path-
ways [91]. Although the mechanism by which the AMPK 
stimulates glucose uptake is not completely defined, most of 
key players involved in this process have been identified. 
One target of AMPK is AS160 protein. This is a GTPase 
activating protein that usually forms a stable complex with 
Rab proteins, a family of small GTP-binding proteins related 
to Ras and involved in the membrane trafficking regulation. 
After insulin stimulation, AS160 is phosphorylated by AKT 
on the same serine residues phosphorylated also by AMPK, 
thus inhibiting its functions. In the absence of insulin or 
metabolic stress stimuli that activate AMPK, the unphos-
phorylated protein AS160 stimulates the GTPase activity of 
Rab, converting it in its inactive GDP-bound form, unable to 
stimulate the transport of the GLUT4 containing vesicles 
towards plasma membrane. Thus, the transport of glucose 
from blood into muscle cells or adipocytes is inhibited. On 
the contrary, when stress stimuli activate AMPK, or insulin 
activates AKT, AS160 becomes phosphorylated, and Rab is 
stabilized in its active GTP-bound form inducing the fusion 
of the vesicles to plasma membrane [92]. AMPK regulates 
also the expression of many genes involved in the control of 
the energetic metabolism. In fact, activated AMPK induces: 
i) the downregulation of the fatty acid synthase (FAS) ex-
pression decreasing the cellular concentration of fatty acid; 
ii) the decrease of cholesterol synthesis [93-96]; iii) the 
upregulation of the peroxisome proliferator-activated recep-
tor- coactivator-1 expression, which consequently in-
creases the mitochondrial biogenesis [97-99]; iv) the upregu-
lation of the hexokinase II and GLUT4 expression in muscle 
cells [97]. In addition, AMPK downregulates the expression 
of both phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase genes in the liver, thereby inhibiting 
gluconeogenesis [100, 101]. 
Natural compounds that target AMPK positively influ-
ence the insulin signaling contributing: i) to stimulate 
GLUT4 translocation onto the plasma membrane of adipo-
cyte and muscle cells; ii) to increase GLUT1/4 expression 
and glucose uptake; iii) to phosphorylate and activate the 
transcriptional co-activator PPAR coactivator-1 (PGC 1). 
PGC 1 is one of the most important transcriptional regula-
tor of mitochondrial gene expression and stimulates both the 
mitochondriogenesis and the mitochondrial oxidative capac-
ity, thereby contributing to fatty acid catabolism. In the liver, 
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expression of key players gluconeogenetic enzymes such as 
phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase; ii) to inhibit the expression of transcription 
factors involved in the regulation of lipids synthesis, such as 
acetyl-CoA carboxylase-1 and fatty acid synthase; iii) to 
increase fatty acid oxidation, through inactivation of the ace-
tyl CoA carboxylase-2, the enzyme that catalyzed the pro-
duction of malonyl-CoA, a potent inhibitor of type-1 car-
nitine acyl tranferase-1. 
Most of compounds listed in Table 2 were tested in vivo
and/or in vitro by using different cellular models, such as 
muscle and liver cells as well as adipocytes. In vivo experi-
ments performed on diabetic or insulin resistant rats or mice, 
revealed that compounds such as nobiletin, EGCG, proan-
thocyanidins, eicosapentaenoic acid, curcumin, berberine, 
galegine, combrestatin A-4, arctigenin, chlorogenic acid, 
salicylate, shikonin stimulate and enhance both basal and 
insulin-mediated glucose transports in muscles, attenuate 
peripheral insulin resistance induced by FFAs, improve the 
symptoms of metabolic syndrome induced by fructose rich-
diet, reduce inflammatory status, contribute to the weight 
loss and improves glucose tolerance in high-fat diet-induced 
obese mice, contributing to normalize blood glucose levels. 
Compelling evidences showed that in vitro, most of these 
substances (quercetin, glyceollin, ursolic acid, naringenin, 
retinoic acid, resveratrol, caffeic acid phenethyl ester, isog-
inkgetin, rutin, (S)-(6)-gingerol, astragalus polysaccharide, 
picetannol, trans-10, cis-12 conjugated linoleic acid, tanger-
itin, monascin and ankaflavin, capsaicin, isodihydrocapsiate, 
-sitosterol, salidroside, damulin A/B, p-cumarinic acid, 
cinnamon, osthole, ascofuranone, tanshinone IIA, pinusolide, 
theasinensins, octaphlorethol A) are able to activate the 
AMPK enzymes, thereby stimulating GLUT4 translocation 
and glucose uptake in muscle cells or adipocytes. Further-
more luteolin, S-allyl-cysteine, theaflavins, and genistein are 
able to influence liver cells metabolism, inhibiting lipids 
synthesis, reducing lipid storage and improving insulin re-
ceptor sensitivity. Finally, additional evidences obtained 
from in vitro studies showed that other compounds (daidzein, 
-carotene, kaempferol 3-neohesperidoside, kaempferitrin, 
pongamol, karanjin, pachymic acid, gallic acid, 4-
hydroxyisoleucine, calophyllic acid and isocalophyllic acid, 
4-hydroxypipecolic acid) stimulate GLUT4 expression 
and/or GLUT4 translocation to plasma membrane, both in 
adipocytes and muscle cells, contributing to increase the rate 
of glucose uptake. 
PPARs Activation by Natural Agonists Increases Insulin 
Sensitivity 
Lipid-rich diets can have deleterious effects on human 
health, favouring a rapid weight gain, insulin resistance and, 
in most cases, the development of T2DM [102]. Triacylglyc-
erols derived from diet or synthesized by liver are trans-
ported in the blood by lipoproteins. The lipoprotein lipase 
present on the wall of blood vessels hydrolyzes triglycerides 
contained in the lipoproteins releasing free fatty acids, which 
are then absorbed by cells. Cellular free fatty acids bind and 
activate the peroxisome proliferator-activated receptors 
(PPARs) which, in turn, upregulates the expression of sev-
eral genes involved in the fatty acid metabolism [103]. Sev-
eral PPAR isotypes (, / and ), which are expressed in 
tissue-specific manner, have been identified. PPAR is ex-
pressed in liver, heart, kidney and skeletal muscle; 
PPAR is mainly present in adipocytes, in several kind of 
immune cells, in the mucosa of colon and cecum, and in pla-
centa, whereas PPAR can be detected in tissues controlling 
lipid metabolism, such as adipocytes, heart, and skeletal 
muscle [104]. These receptors act as metabolic sensors and 
are able to modulate, depending on the nutrient availability, 
the expression of several genes codifying enzymes involved 
in the control of energetic metabolism (Fig. 4). For example, 
in muscle, liver and heart, PPAR stimulates the transcrip-
tion of genes involved in fatty oxidation, thereby repro-
gramming cells to high-capacity fatty acid metabolism [105]. 
Nevertheless, when the fatty acids availability exceeds the 
cells oxidative capability, cells undergoes to metabolic over-
load, resulting in mitochondrial disfunction (Fig. 5) [106]. 
The presence of mitochondrial abnormalities accompanied 
by high fatty acid levels in most of muscle and liver cells of 
subjects affected by insulin resistance or T2DM confirms 
this hypothesis [107-109]. The excess fatty acids are esteri-
fied and either stored or metabolized to various intermediates 
such as diacylglycerols, ceramides and triglycerides, result-
ing in a significant accumulation into cytoplasm or endo-
plasmic reticulum. Diacylglycerols activate the protein 
kinase C theta isoform (PKC	) which, in turn, phosphory-
lates IRS-1 on serine residues, inhibiting its functions. Thus, 
signaling events downstream insulin receptor, such as the 
activation of PI3K and AKT, GLUT4 translocation onto the 
plasma membrane, and glycogen synthesis are impaired. On 
the other hand, ceramides activate protein kinase C zeta iso-
form (PKC) and protein phosphatase 2A, which collaborate 
to inhibit both translocation and activation of AKT onto the 
plasma membrane, thereby contributing to reduce insulin 
sensitivity [110]. Finally, accumulation of fatty acids in the 
endoplasmic reticulum induces a stress condition resulting in 
the activation of the stress activated Janus kinase (JNK), 
which phosphorylates IRS-1 [111]. In addition, ER stress 
contributes to increase PTP1B expression and leads to insu-
lin resistance in muscle cells, suggesting a link between ER 
stress and the pathogenesis of obesity-associated insulin re-
sistance (Fig. 5) [112]. Hence, the stimulation of PPARs 
activity is an effective strategy to lower blood lipid levels as 
well as to increase the insulin sensitivity, overcoming the 
problem of insulin resistance [113]. In the last decades, sev-
eral synthetic agonists of PPARs have been produced, but 
only few of them, such as fibrates (clofibrate, fenofibrate, 
bezafibrate) and thiazolidinediones (rosiglitazone and piogli-
tazone) have been approved for treatment of T2DM and 
metabolic syndrome. Thiazolidinediones show antidiabetic 
activity in patients affected by T2DM, since they increase 
insulin sensitivity, stimulate glucose uptake, and decrease the 
levels of insulin and glycated hemoglobin. The efficacy of 
PPAR agonists is in part attributable to reduction of lipotox-
icity in skeletal muscle and liver, and in part is probably due 
to their ability to stimulate the expression of glucose trans-
porters GLUT1 and GLUT4 or of other intracellular proteins 
such as c-Cbl-associated protein (CAP) [114, 115]. Further-
more, it has been demonstrated that PPAR agonists are able 
to stimulate adiponectin expression, which, in turn, increases 
fatty acid oxidation through an AMPK-dependent mecha-
nism in liver and muscle, and decreases glucose production 
in liver [116]. In addition, PPAR activation correlates with 
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Table 2. Natural substances that increase glucose uptake acting through the AMPK activation. 
Compound Main Biological Effects Source 
Quercetin and quercetin gly-
cosides
Stimulation of AMPK and glucose uptake in muscle cells [186] Vaccinium vitis-idaea 
Glyceollin
Enhancement of insulin sensitivity in db/db mice muscle under ER stress condi-
tions through activation of AMPK [187] 
Derived from daidzein in soybeans in-
fected by fungi 
Luteolin Activation of AMPK in HepG2 cells [188] Several plant species 
S-allyl cysteine Activation of AMPK through Ca2+/calmodulin-dependent kinase kinase [189] Allium sativum 
Nobiletin
Increase of phospho-Akt and GLUT1 and GLUT4 expression in white adipose 
tissue and muscle [190]; Increase of hepatic and peripheral insulin sensitivity 
[191] 
Fruits of Citrus species 
Ursolic acid Activation of LKB1/AMPK pathway [192] Several plant species 
Epigallocatechin gallate (EGCG)
Attenuation of peripheral insulin resistance through AMPK pathway in vivo 
[193]; activation of IRS2 and AMPK signaling in rat pancreatic -cells [194]; 
activation of the LKB1/AMPK pathway [195]; suppression of hepatic glu-
coneogenesis through the AMPK [196] 
Camellia sinensis 
Theaflavins Decrease of hepatic lipid accumulation trough the LKB1/AMPK pathway [197] Several species of tea (leaves) 
Naringenin Increases muscle cell glucose uptake via AMPK [198] Citrus paradisi 
Genistein
Activation of PGC-1, upregulation of GLUT1 expression. Reversion of free 




Enhancement of insulin-stimulated glucose uptake in adipocytes by increasing 
the expression of GLUT4 and IRS1 via the activation of PPAR [200] Some plant and herb species 
Proanthocyanidin-rich extract Enhancement of IRS1 and GLUT4 expression [201] Malus domestica 
Retinoic acid Activation of AMPK in skeletal muscle cells [202] Vegetables fonts (vitamin A metabolite) 
Eicosapentaenoic acid
Increase of GLUT4 expession in muscle and 2-deoxy-D-glucose uptake in 
C2C12 myotubes [203] 
Vegetable and fish fonts 
Curcumin Activation of LKB1/AMPK pathway [204] Curcuma longa 
Resveratrol Activation of PGC-1 and AMPK [205] Fruiting berry of Vitis vinifera
Caffeic acid phenethyl ester Activation of AMPK in skeletal muscle [206] Several plants and honey 
Berberine Activation of AMPK [207]; [208] 
Several Berberis species and a variety of 
other plant species 
Isoginkgetin Enhances adiponectin secretion through AMPK activation [209] Ginkgo biloba 
Galegine




Enhance the expression of genes related to insulin sensitivity, including GLUT4
and adiponectin [211]. Decrease blood glucose [212] 
Daucus carota and other plant species 
Rutin
Increase of glucose uptake in rat soleus muscle, enhancing GLUT4 synthesis 
and translocation [213] 
Ginkgo biloba and other plant species 
Kaempferol 3-neohesperidoside
Stimulation of glucose uptake in the rat soleus muscle via the PI3K and PKC 
pathways, and of the synthesis of new glucose transporters [214] 
Several plant species 
Kaempferitrin
Activation of the classical insulin transduction pathway in adipocytes. Increased
expression and translocation of GLUT4 to the membrane [215] 
Leaves of various plant species 
(S)-(6)-Gingerol Enhancement glucose uptake in L6 myotubes by activation of AMPK [216] Zingiber officinale 
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(Table 2) contd…. 
Compound Main Biological Effects Source 
Astragalus polysaccharide




Promotion of glucose uptake, AMPK phosphorylation and GLUT4 transloca-
tion in L6 myotubes [218] 
Picea abies 
trans-10, cis-12 conjugated lino-
leic acid
Activation of PI3K, AMPK and AS160 in skeletal muscle [219] 
Produced from linoleic acid in the rumen 
by microbes [220] 
Tangeritin
Stimulation of glucose uptake via the AMPK signaling pathways in C2C12 
myotubes [221] 
Fruits of Citrus species 
Monascin and ankaflavin Activation of AMPK in mice [222] Monascus purpureus 
Combrestatin A-4 Activation of AMPK in mice [223] Combretum caffrum 
Capsaicin Activation of AMPK in C2C12 cells [224] Capsicum species 
Isodihydrocapsiate Stimulation of glucose uptake by activation of AMPK [225] Capsicum species 
-sitosterol Activation of AMPK in L6 myotubes [226] Several plant species 
Salidroside
Stimulation of glucose uptake in skeletal muscle cells by activation of AMPK 
[227] 
Rhodiola rosea 
Damulin A/B Activation of AMPK in L6 myotube cells [228] Gynostemma pentaphyllum 
p-Coumaric acid Activation of AMPK in L6 skeletal muscle cells [229] A variety of edible plants 
Arctigenin Activation of AMPK in ob/ob mice [230] Asteraceae 
Chlorogenic acid Stimulation of glucose transport in skeletal muscle via AMPK activation [231 ] Several plant species 
Salicylate
Activation of AMPK [232]. Reversion of hyperglycaemia, hyperinsulinemia, 
and dyslipidemia in obese rodents by sensitizing insulin signaling [233] 
Salix alba 
Cinnamon extract
Enhancement of glucose uptake in 3T3-L1 Adipocytes and C2C12 Myocytes by
inducing LKB1-AMPK signaling [234] 
Cinnamomum verum 
Osthole




Stimulation of both glucose transport and GLUT4 translocation to the cell sur-
face of L6 myotubes [236] 
Pongamia pinnata 
Karanjin
Increase in glucose uptake in L6 myotubes and translocation of GLUT4 to 
plasma membrane associated with activation of AMPK pathway [237] 
Pongamia pinnata 
Pachymic acid
Stimulation of glucose uptake and GLUT4 expression and translocation in 
adipocytes . Both PI3K and AMPK are involved in the above actions [238] 
Poria cocos 
Gallic acid Stimulation of glucose uptake and GLUT4 translocation in 3T3-L1 cells [239] Hippophae rhamnoides 
4-hydroxyisoleucine
Stimulation of glucose uptake and GLUT4 translocation in skeletal muscle cells
in a PI3K/AKT-dependent mechanism [240] 
Trigonella foenum-graecum 
Calophyllic acid and isocalo-
phyllic acid
Stimulation of glucose uptake and GLUT4 translocation in L6 myotubes 




Stimulation of both glucose uptake and GLUT4 translocation to cell surface in 
skeletal muscle cells [242] 
Peganum harmala Linn
Ascofuranone AMPK activation in L6 myotube cells [243] Ascochyta viciae 
Tanshinone IIA
AMPK activation in L6 myotubes and reduction of blood glucose levels in 
db/db mice [244] 
Salvia miltiorrhiza bunge
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(Table 2) contd…. 
Compound Main Biological Effects Source 
Pinusolide
Enhancement of IRS-1 tyrosine phosphorylation by the activating the AMPK 
pathway in muscle cells [245] 
Biota orientalis 
Theasinensins
Stimulation of glucose uptake through the AMPK pathway in rat skeletal mus-
cle cells [246] 
Camellia sinensis 
Octaphlorethol A
Increase of both GLUT4 translocation to the plasma membrane and glucose 




Shikonin increases glucose uptake in skeletal muscle cells via an insulin-
independent pathway dependent on calcium [248] 
Lithospermum erythrorhizon 
Fig. (4). Activation of PPARs by natural agonists increase insulin sensitivity. Several natural compounds, mimicking natural agonist, bind 
PPARs and stimulate their transcriptional activity. Consequently, the expression of several genes involved in lipids metabolism, such as those 
involved in fatty acid and glucose transport, -oxidation, mitochondrial respiration and biogenesis, is strongly increased. Activation of PPARs 
favors adipocyte differentiation and lipid storage in the subcutaneous adipose tissue, thereby decreasing the levels of blood fatty acids. In 
addition, natural PPARs agonists reduce the release of inflammatory cytokines from visceral adipose tissue, thus inhibiting JNK activation in 
the peripheral tissues such as liver and muscle. The increase of lipid metabolism leads to reduction of intracellular depots, downregulating the 
activity of PKC, PKC and PP2A, thereby resulting in an increase of insulin sensitivity. The decrease of fatty acid levels in the hepatocytes 
and muscle cells alleviates ER stress, leading to downregulation of PTP1B expression and improving the insulin signaling pathway. For an 
explanation of acronyms see 'Abbreviations'. 
expression of genes involved in fatty acid oxidation or/and 
with expression of uncoupling proteins in brown adipose 
tissue and in skeletal muscle [117, 118]. Compelling evi-
dences demonstrated that in muscle cells PPAR agonists 
stimulate glucose uptake through an AMPK and/or p38-
MAPK-dependent signaling pathways, and that they are able 
to decrease glucose production in the liver [119, 120]. 
Although the known efficacy of the commercially avail-
able PPARs agonists, these drugs have adverse effects in 
humans, hence the research in this field is still very active. In 
the last years it has been demonstrated that many natural 
compounds are able to act as agonist of PPARs, contributing 
to stimulate insulin activity, glucose uptake and fatty acid 
metabolism, both in vitro and in vivo. In Table 3 most of 
known natural agonists of PPARs are listed. 
CONCLUSION 
Nowadays, the tendency to a sedentary lifestyle and obe-
sity are becoming a serious problem in many western coun-
tries. Epidemiological analysis show that a growing number 
of individuals suffer of systemic insulin resistance, T2DM 
and/or metabolic syndrome. Drugs currently available to 
counteract these diseases are often characterized by a low 
effectiveness, unexpected side effects and ido not provide 
adequate protection against the many complications of these 
diseases. Many studies demonstrated that natural dietary 
compounds exert beneficial effects on human health, im-
proving insulin signaling pathway and contributing to a bet-
ter control of energy homeostasis, both in health humans that 
in diabetic subjects. For this reason many researches agree 
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Fig. (5). Intracellular lipid overload leads to impaired insulin signaling. Intracellular lipid accumulation stimulates PKC activation that 
inhibits IRSs. Similarly, ceramides stimulate PKC and PP2A activation, decreasing activity of AKT. On the other hand, excessive storage of 
lipids into endoplasmic reticulum trigger stress response that leads to activation of JNK which increase serine phosphorylation of IRS-1, im-
pairing insulin signaling. JNK is also activated by inflammatory cytokines, suggesting a link between obesity, chronic inflammation and insu-
lin resistance. ER stress causes elevation in PTP1B levels, which targets IR and IRS-1, decreasing insulin sensitivity. 
Table 3. Natural agonists of PPARs. 
Compound Main Biological Effects Source 
Monascin and Ankaflavin PPAR agonist [222] Monascus-fermented rice 
Astaxanthin PPAR agonist PPAR antagonist [249] A natural carotenoid abundant in seafood 
Ursolic acid PPAR agonist [250] Actinidia arguta
Auraptene PPAR and PPAR agonist [251] Fruit of Citrus species 
Phytol PPAR agonist [252] a component of chlorophylls 
Amorfrutin B PPAR agonist [253] Glycyrrhiza foetida
Sargaquinoic acid and Sargahydroquinoic acid PPAR and PPAR agonist[254] Sargassum yezoense
Ionomycin PPAR agonist [255] Streptomyces conglobatus
Phosphoiodyns A PPAR agonist [256] Placospongia sp.
Herdmanine I and K PPAR agonist [257] Herdmania momus
Gracilioether B and Plakilactone C PPAR agonist [258] Plakinastrella mamillaris
Psammaplin A PPAR agonist [259] Pseudoceratina rhax
Bixin PPAR agonist [260] Bixa orellana
Ginsenoside 20(S)-Protopanaxatriol PPAR agonist [261] Ginseng saponin 
Astaxanthin PPAR and PPAR agonist [249] 
microalgae, yeast, salmon, and most crustaceans, 
including krill, shrimp, crawfish, crabs, and lobster 
-Lipoic acid PPAR agonist [262] broccoli, spinach and tomatoes 
Paecilocin A PPAR agonist [263] Paecilomyces variotii
Honokiol PPAR agonists [264] Magnolia bark 
Magnolol PPAR agonists [265] Magnolia officinalis
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(Table 3) contd…. 
Compound Main Biological Effects Source 
Emodin PPAR agonists [266] Rheum palmatum L
Kaempferol and Quercetin PPAR agonists [267] Euonymus alatus 
Daidzein PPAR agonists [200] Soy and other plant and herb species 
Artepillin C PPAR agonists [268] Baccharis dracunculifolia 
Linoleic acid, -Linolenic acid, Arachidonic acid 
and Eicosapentaenoic acid
PPAR agonists [269]  
Ankaflavin PPAR agonist [270] Monascus-fermented rice 
Amorphastilbol PPAR, PPAR agonist [271] Amorpha fruticosa
Luteolin PPAR agonist [272] Several plant species 
(-)-Catechin PPAR agonist [273] Camellia sinensis 
-baptigenin PPAR and PPAR agonist [274] Trifolium pratense
Apigenin PPAR and PPAR agonist [274] Several plants 
Acacetin PPAR and PPAR agonist [274]
Robinia pseudoacacia, Turnera diffusa, Asplenium 
normale
Chrysoeriol PPAR and PPAR agonist [274] Artemisia copa
Diosmetin PPAR and PPAR agonist [274] Caucasian vetch plants 
Chrysin PPAR and PPAR agonist [274] Several plants 
Kaempferol PPAR and PPAR agonist [274] Several plants 
Catalposide PPAR agonist [275] Catalpa ovata
Chlorophellins A PPAR agonist [276] Phellinus ribis
Chlorophellins B PPAR agonist [276] Phellinus ribis
Chlorophellin C PPAR agonist [276] Phellinus ribis
Drosophilin A PPAR agonist [276] Phellinus ribis
Hesperidin PPAR agonist [277 ] Citrus fruits 
effective strategy to prevent the onset and diffusion of 
chronic degenerative diseases such as T2DM. Traditional 
medicines, and in particular traditional Chinese medicine, 
use several plants preparations to treat diabetes and diabetic 
complications without side-effects. These herbal prepara-
tions contain tens of constituents, whose formulation is not 
standardizable. Thus in the last decades many efforts have 
been made attempting to identify compounds inside these 
preparation responsible for the hypoglycaemic effect. For 
example, metformin, a widely used hypoglycaemic drug, 
was purified from the traditional preparation of Galega offi-
cinalis. Several natural compounds have been shown to 
modulate the activity of specific enzymes and/or signaling 
molecules involved in the glycaemic control. Some of these 
compounds are in trial III phase to confirm their actual effec-
tiveness on humans. 
ABBREVIATIONS 
ADP = Adenosine diphosphate 
Akt/PKB = Protein kinase B 
AMPK = AMP-activated protein kinase 
AS160 = Akt substrate of 160 kDa 
ATP = Adenosine triphosphate 
CAP = Catabolite Activator Protein 
CD45 = Leukocyte common antigen, protein tyrosine 
phosphatase 
CHO/hIR = Chinese hamster ovary cell transfected with 
insulin receptor gene 
DAG = Diacylglycerol 
DM = Diabetes mellitus 
EGFR = Epidermal growth factor receptor 
ER = Endoplasmic reticulum 
ERK = Extracellular signal-regulated kinase 
ERK = extracellular signal-regulated kinases 
FABP = Fatty acid binding protein 
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FAT/CD36 = Fatty acid transporter 
FATP = Fatty acid transport proteins
FOXO = Forkhead transcription factors 
GAP = GTPase activating protein 
GLUT4 = Glucose transporter type 4 
Grb2 = Growth factor receptor-bound protein 2 
GS = Glycogen synthase 
GSK3 = Glycogen synthase kinase 3 
HepG2 = Human hepatocellular liver carcinoma cell
line 
IR = Insulin receptor 
IRS = Insulin receptor substrate 
JNK = c-Jun N-terminal kinases 
JNK = Jun N-terminal kinase 
LAR = Leucocyte antigen related phosphatase 
LMW-PTP = Low Molecular Weight Protein Tyrosine 
Phosphatase 
MAPK = Mitogen activated protein kinases 
MptpB = Mycobacterium tuberculosis Protein Tyro-
sine Phosphatases 
p70S6K = Ribosomal protein S6 kinase beta-1 
PDE = Phosphodiesterase 
PDGFR = Platelet derived growth factor receptor 
PDK1 = Phosphoinositide-dependent kinase 1 
PEPCK = Phosphoenolpyruvate carboxykinase 
PGC = Peroxisome proliferator-activated receptor 
gamma coactivator 
PI3K = Phosphatidylinositol 3-kinase 
PIP3 = Phosphatidylinositol (3,4,5)-triphosphate
PKC = Protein kinase C 
PKD = Protein kinase D 
PPAR = Peroxisome proliferator-activated receptors 
PTP1B = Protein Tyrosine Phophatases 1B 
PTPs = Protein Tyrosine Phophatases 
SHC = Src homology 2 domain containing) trans-
forming protein 
SHP-2 = Src homology-2 domain-containing phospha-
tase 
SOS = Son of sevenless 
SREB1 = Sterol regulatory element-binding protein 1 
STAT3 = Signal transducer and activator of transcrip-
tion 3 
T2DM = Type 2 diabetes mellitus 
TC-PTP = T-Cell Protein Tyrosine Phosphatase 
TORC1 = Transcriptional coactivator for CREB1 
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